Selected research
Industry Research
Plant Derivative Drug Industry Research Report 2026
Market perspective
The global Plant Derivative Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Plant Derivative Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Plant Derivative Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Plant Derivative Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Plant Derivative Drug include Yunnan Baiyao, Weleda, Tsumura, Tong Ren Tang, Tasly Holding Group, Taiji, Schwabe, Kwangdong and Jumpcan Pharmaceutical, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Plant Derivative Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Plant Derivative Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Plant Derivative Drug Market by Company
Yunnan Baiyao
Weleda
Tsumura
Tong Ren Tang
Tasly Holding Group
Taiji
Schwabe
Kwangdong
Jumpcan Pharmaceutical
Huarun 999
GW Pharmaceuticals
Guangzhou Baiyunshan Pharmaceutical
China TCM
Buchang Pharmaceuticals
Bionorica Se
Plant Derivative Drug Segment by Type
Prescription Drug
OTC
Plant Derivative Drug Segment by Application
Tumor
Cardiovascular
Respiratory System
Other
Plant Derivative Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plant Derivative Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plant Derivative Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plant Derivative Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Plant Derivative Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prescription Drug
- OTC
Applications
- Tumor
- Cardiovascular
- Respiratory System
- Other
Companies covered
- Yunnan Baiyao
- Weleda
- Tsumura
- Tong Ren Tang
- Tasly Holding Group
- Taiji
- Schwabe
- Kwangdong
- Jumpcan Pharmaceutical
- Huarun 999
- GW Pharmaceuticals
- Guangzhou Baiyunshan Pharmaceutical
- China TCM
- Buchang Pharmaceuticals
- Bionorica Se
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Plant Derivative Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Prescription Drug
- 2.2.3 OTC
- 2.3 Plant Derivative Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Tumor
- 2.3.3 Cardiovascular
- 2.3.4 Respiratory System
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Plant Derivative Drug Breakdown Data by Type
- 3.1 Global Plant Derivative Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Plant Derivative Drug Forecasted Market Size by Type (2027-2032)
4 Plant Derivative Drug Breakdown Data by Application
- 4.1 Global Plant Derivative Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Plant Derivative Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Plant Derivative Drug Market Perspective (2021-2032)
- 5.2 Global Plant Derivative Drug Growth Trends by Region
- 5.2.1 Global Plant Derivative Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Plant Derivative Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Plant Derivative Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Plant Derivative Drug Market Dynamics
- 5.3.1 Plant Derivative Drug Industry Trends
- 5.3.2 Plant Derivative Drug Market Drivers
- 5.3.3 Plant Derivative Drug Market Challenges
- 5.3.4 Plant Derivative Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Plant Derivative Drug Players by Revenue
- 6.1.1 Global Top Plant Derivative Drug Players by Revenue (2021-2026)
- 6.1.2 Global Plant Derivative Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Plant Derivative Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Plant Derivative Drug Head Office and Area Served
- 6.4 Global Plant Derivative Drug Players, Product Type & Application
- 6.5 Global Plant Derivative Drug Manufacturers Established Date
- 6.6 Global Plant Derivative Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Plant Derivative Drug Market Size (2021-2032)
- 7.2 North America Plant Derivative Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Plant Derivative Drug Market Size by Country (2021-2026)
- 7.4 North America Plant Derivative Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Plant Derivative Drug Market Size (2021-2032)
- 8.2 Europe Plant Derivative Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Plant Derivative Drug Market Size by Country (2021-2026)
- 8.4 Europe Plant Derivative Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Plant Derivative Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Plant Derivative Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Plant Derivative Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Plant Derivative Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Plant Derivative Drug Market Size (2021-2032)
- 10.2 South America Plant Derivative Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Plant Derivative Drug Market Size by Country (2021-2026)
- 10.4 South America Plant Derivative Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Plant Derivative Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Plant Derivative Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Plant Derivative Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Plant Derivative Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Yunnan Baiyao
- 12.1.1 Yunnan Baiyao Company Information
- 12.1.2 Yunnan Baiyao Business Overview
- 12.1.3 Yunnan Baiyao Revenue in Plant Derivative Drug Business (2021-2026)
- 12.1.4 Yunnan Baiyao Plant Derivative Drug Product Portfolio
- 12.1.5 Yunnan Baiyao Recent Developments
- 12.2 Weleda
- 12.2.1 Weleda Company Information
- 12.2.2 Weleda Business Overview
- 12.2.3 Weleda Revenue in Plant Derivative Drug Business (2021-2026)
- 12.2.4 Weleda Plant Derivative Drug Product Portfolio
- 12.2.5 Weleda Recent Developments
- 12.3 Tsumura
- 12.3.1 Tsumura Company Information
- 12.3.2 Tsumura Business Overview
- 12.3.3 Tsumura Revenue in Plant Derivative Drug Business (2021-2026)
- 12.3.4 Tsumura Plant Derivative Drug Product Portfolio
- 12.3.5 Tsumura Recent Developments
- 12.4 Tong Ren Tang
- 12.4.1 Tong Ren Tang Company Information
- 12.4.2 Tong Ren Tang Business Overview
- 12.4.3 Tong Ren Tang Revenue in Plant Derivative Drug Business (2021-2026)
- 12.4.4 Tong Ren Tang Plant Derivative Drug Product Portfolio
- 12.4.5 Tong Ren Tang Recent Developments
- 12.5 Tasly Holding Group
- 12.5.1 Tasly Holding Group Company Information
- 12.5.2 Tasly Holding Group Business Overview
- 12.5.3 Tasly Holding Group Revenue in Plant Derivative Drug Business (2021-2026)
- 12.5.4 Tasly Holding Group Plant Derivative Drug Product Portfolio
- 12.5.5 Tasly Holding Group Recent Developments
- 12.6 Taiji
- 12.6.1 Taiji Company Information
- 12.6.2 Taiji Business Overview
- 12.6.3 Taiji Revenue in Plant Derivative Drug Business (2021-2026)
- 12.6.4 Taiji Plant Derivative Drug Product Portfolio
- 12.6.5 Taiji Recent Developments
- 12.7 Schwabe
- 12.7.1 Schwabe Company Information
- 12.7.2 Schwabe Business Overview
- 12.7.3 Schwabe Revenue in Plant Derivative Drug Business (2021-2026)
- 12.7.4 Schwabe Plant Derivative Drug Product Portfolio
- 12.7.5 Schwabe Recent Developments
- 12.8 Kwangdong
- 12.8.1 Kwangdong Company Information
- 12.8.2 Kwangdong Business Overview
- 12.8.3 Kwangdong Revenue in Plant Derivative Drug Business (2021-2026)
- 12.8.4 Kwangdong Plant Derivative Drug Product Portfolio
- 12.8.5 Kwangdong Recent Developments
- 12.9 Jumpcan Pharmaceutical
- 12.9.1 Jumpcan Pharmaceutical Company Information
- 12.9.2 Jumpcan Pharmaceutical Business Overview
- 12.9.3 Jumpcan Pharmaceutical Revenue in Plant Derivative Drug Business (2021-2026)
- 12.9.4 Jumpcan Pharmaceutical Plant Derivative Drug Product Portfolio
- 12.9.5 Jumpcan Pharmaceutical Recent Developments
- 12.10 Huarun 999
- 12.10.1 Huarun 999 Company Information
- 12.10.2 Huarun 999 Business Overview
- 12.10.3 Huarun 999 Revenue in Plant Derivative Drug Business (2021-2026)
- 12.10.4 Huarun 999 Plant Derivative Drug Product Portfolio
- 12.10.5 Huarun 999 Recent Developments
- 12.11 GW Pharmaceuticals
- 12.11.1 GW Pharmaceuticals Company Information
- 12.11.2 GW Pharmaceuticals Business Overview
- 12.11.3 GW Pharmaceuticals Revenue in Plant Derivative Drug Business (2021-2026)
- 12.11.4 GW Pharmaceuticals Plant Derivative Drug Product Portfolio
- 12.11.5 GW Pharmaceuticals Recent Developments
- 12.12 Guangzhou Baiyunshan Pharmaceutical
- 12.12.1 Guangzhou Baiyunshan Pharmaceutical Company Information
- 12.12.2 Guangzhou Baiyunshan Pharmaceutical Business Overview
- 12.12.3 Guangzhou Baiyunshan Pharmaceutical Revenue in Plant Derivative Drug Business (2021-2026)
- 12.12.4 Guangzhou Baiyunshan Pharmaceutical Plant Derivative Drug Product Portfolio
- 12.12.5 Guangzhou Baiyunshan Pharmaceutical Recent Developments
- 12.13 China TCM
- 12.13.1 China TCM Company Information
- 12.13.2 China TCM Business Overview
- 12.13.3 China TCM Revenue in Plant Derivative Drug Business (2021-2026)
- 12.13.4 China TCM Plant Derivative Drug Product Portfolio
- 12.13.5 China TCM Recent Developments
- 12.14 Buchang Pharmaceuticals
- 12.14.1 Buchang Pharmaceuticals Company Information
- 12.14.2 Buchang Pharmaceuticals Business Overview
- 12.14.3 Buchang Pharmaceuticals Revenue in Plant Derivative Drug Business (2021-2026)
- 12.14.4 Buchang Pharmaceuticals Plant Derivative Drug Product Portfolio
- 12.14.5 Buchang Pharmaceuticals Recent Developments
- 12.15 Bionorica Se
- 12.15.1 Bionorica Se Company Information
- 12.15.2 Bionorica Se Business Overview
- 12.15.3 Bionorica Se Revenue in Plant Derivative Drug Business (2021-2026)
- 12.15.4 Bionorica Se Plant Derivative Drug Product Portfolio
- 12.15.5 Bionorica Se Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst